B-cell receptor (BCR) specific for HIV-1 Trans-Activator of Transcription (Tat) epitopes (BCR-Tat)

The B-cell receptor (BCR) specific for HIV-1 Trans-Activator of Transcription (Tat) epitopes is a specialized surface immunoglobulin on B-lymphocytes that plays a critical role in the adaptive immune response against HIV-1. Tat is a potent regulatory protein essential for viral gene expression that is actively secreted by infected cells, contributing significantly to immune dysfunction, chronic inflammation, and HIV-associated neurocognitive disorders (Ensoli et al., 2015). Therapeutic vaccines, such as the ISS-T002 candidate, are designed to target these specific BCRs to stimulate the clonal expansion of B-cells and the production of high-affinity neutralizing antibodies (Ensoli et al., 2016). These antibodies sequester extracellular Tat, preventing its entry into uninfected cells and inhibiting the transactivation of the HIV-1 provirus. Engaging these BCRs is a strategic approach intended to complement antiretroviral therapy (ART) by restoring immune homeostasis and reducing the persistent viral reservoir. Clinical trials have demonstrated that targeting this receptor can lead to a significant reduction in proviral DNA and an increase in CD4+ T-cell counts in treated patients (Ensoli et al., 2010).

Other names

Tat-specific B-cell receptorAnti-HIV-1 Tat BCRB-cell receptor for Trans-Activator of TranscriptionHIV-1 Tat-specific immunoglobulin receptor

Vaccine-mediated stimulation of specific B-cell receptors to induce the production of neutralizing antibodies that sequester extracellular HIV-1 Tat protein, thereby inhibiting viral transactivation and immune dysregulation.